Clinical and Ultrasonographic Changes of the Breast after Use of Soy Isoflavones

  • Alipour, Sadaf (Surgery Department, Arash women's Hospital) ;
  • Afshar, Somayeh (Gynecology Department, Arash women's Hospital) ;
  • Moini, Ashraf (Gynecology Department, Arash women's Hospital) ;
  • Dastjerdi, Marzieh Vahid (Gynecology Department, Arash women's Hospital) ;
  • Saberi, Azin (Surgery Department, Arash women's Hospital) ;
  • Bayani, Leila (Radiology Department, Arash women's Hospital) ;
  • Eslami, Bita (Development Center, Arash women's Hospital, Tehran University of Medical Sciences) ;
  • Hosseini, Ladan (Development Center, Arash women's Hospital, Tehran University of Medical Sciences)
  • Published : 2012.12.31


Background: Phytoestrogens may be an alternative therapy in control of menopausal symptoms but their definite effects on breast tissue must be determined. Our study aimed to define the clinical and ultrasonographic changes of the breast after use of soy isoflavones in menopausal women. Materials and Methods: Menopausal women with hot flashes were randomly grouped as cases and controls and cases received soy isoflavones for 12 weeks. Breast examination (BE) and ultrasonography (US) were done at 0, 6 and 12 weeks. Tenderness and nodularity on BE were graded 1-4 by breast surgeons. Results: There were 30 women in the case and 26 in the control group. The mean age was 51.3 years and the mean age of menopause was 49.2 years. There was no change in the BE and US at 6 weeks in controls. In the case group, 10% had grade 1 tenderness and 13.3% grade 2 tenderness and grade 1 nodularity in BE accompanied with diffuse small cysts in US. At 12 weeks, there was no change in BE and US in the 2 groups. Conclusions: There was no statistically significant difference in the BE of the 2 groups at 6 and 12 weeks (p value=0.36 and 0.41 for nodularity and tenderness respectively) and in the US results. Although the literature contains many facts concerning PEs and the breast, further prospective studies are needed to identify structural breast changes produced by PEs in order to identify the appropriate dosage and indications of use.


Breast examination;breast neoplasm;ultrasonography;phytoestrogens;soy isoflavones


  1. Pelekanou V, Leclercq G (2011). Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis. Int J Dev Biol, 55, 869-78.
  2. Tempfer CB, Froese G, Heinze G, et al (2009). Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med, 122, 939-46.
  3. van Duursen MB, Nijmeijer SM, de Morree ES, et al (2011). Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model. Toxicology, 289, 67-73.
  4. Zaineddin AK, Buck K, Vrieling A, et al (2012). The association between dietary lignans, phytoestrogen-rich foods, and fiber intake and postmenopausal breast cancer risk: a German case-control study. Nutr Cancer, 64, 652-65
  5. Zhang M, Liu X, Holman CD (2010). Effect of dietary intake of isoflavones on the estrogen and progesterone receptor status of breast cancer. Nutr Cancer, 62, 765-73.
  6. Anderson LN, Cotterchio M, Boucher BA, et al (2012). Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor (ERPR) tumour subgroup among Ontario women. Int J Cancer, ahead of printing.
  7. Bolca S, Urpi-Sarda M, Blondeel P, et al (2010). Disposition of soy isoflavones in normal human breast tissue. Am J Clin Nutr, 91, 976-84.
  8. Bondesson M, Gustafsson JA (2010). Does consuming isoflavones reduce or increase breast cancer risk? Genome Med, 2, 90.
  9. Buck K, Zaineddin AK, Vrieling A, et al (2010). Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr, 92, 141-53.
  10. Cotterchio M, Boucher BA, Kreiger N, et al (2008). Dietary phytoestrogen intake--lignans and isoflavones--and breast cancer risk (Canada). Cancer Causes Control, 19, 259-72.
  11. Dave B, Wynne R, Su Y, et al (2010). Enhanced mammary progesterone receptor-A isoform activity in the promotion of mammary tumor progression by dietary soy in rats. Nutr Cancer, 62, 774-82.
  12. Goodman MT, Shvetsov YB, Wilkens LR, et al (2009). Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Prev Res (Phila), 2, 887-94.
  13. Hedelin M, Lof M, Olsson M, et al (2008). Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast tumors in Swedish women. J Nutr, 138, 938-45.
  14. Iwasaki M, Inoue M, Otani T, et al (2008). Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol, 26, 1677-83.
  15. Kim HA, Jeong KS, Kim YK (2008). Soy extract is more potent than genistein on tumor growth inhibition. Anticancer Res, 28, 2837-41.
  16. Liu MM, Huang Y, Wang J (2012). Developing Phytoestrogens for Breast Cancer Prevention. Anticancer Agents Med Chem, Ahead of printing
  17. Lowry SJ, Sprague BL, Aiello Bowles EJ, et al (2012). Mammographic breast density and serum phytoestrogen levels. Nutr Cancer, 64, 783-9.
  18. Martinez-Montemayor MM, Otero-Franqui E, Martinez J, et al (2010). Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. Clin Exp Metastasis, 27, 465-80.
  19. Mense SM, Hei TK, Ganju RK et al (2008). Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Hlth Perspect, 116, 426-33.
  20. Morimoto Y, Conroy SM, Pagano IS, et al (2012). Urinary estrogen metabolites during a randomized soy trial. Nutr Cancer, 64, 307-14.